登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
- 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07739758,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
入选标准第 4 条
History of immune-related adverse events (irAEs) of CTCAE Grade ≥3 during prior immunotherapy, or unresolved adverse events from previous antitumor therapy.
排除标准第 2 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 3 条
At least one extracranial measurable lesion according to RECIST v1.1.
入选标准第 6 条
History of immunodeficiency or positive for human immunodeficiency virus (HIV) antibodies test.
排除标准第 11 条
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Participants with inactive HBV infection must receive antiviral therapy throughout the study.
排除标准第 12 条
History of other primary malignancies within 5 years prior to randomization.
排除标准第 13 条
Females who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study period.
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07739758,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the written informed consent form and comply with the protocol requirements Age ≥18 years. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). No prior systemic treatment for ES-SCLC. At least one extracranial measurable lesion according to RECIST v1.1. Adequate organ function. Life expectancy ≥3 months.排除标准:Exclusion Criteria:
Any histological types of transformed SCLC or combined SCLC. History of immune-related adverse events (irAEs) of CTCAE Grade ≥3 during prior immunotherapy, or unresolved adverse events from previous antitumor therapy. Major surgery (excluding diagnostic procedures) or severe trauma within 4 weeks prior to randomization or planned major surgery during the study period. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. Presence of active brain metastases, brainstem metastases, or leptomeningeal metastases. Presence of severe and uncontrolled cardiovascular or cerebrovascular disease. History of interstitial lung disease (ILD) /pneumonitis requiring steroid treatment, or current diagnosis of ILD/pneumonitis, or concurrent pulmonary disease leading to clinically severe impairment of respiratory function. Active autoimmune or inflammatory diseases within 2 years prior to randomization. Severe infection within 4 weeks prior to randomization, or active infection requiring intravenous anti-infective therapy within 2 weeks or oral anti-infective therapy within 1 week prior to randomization. Known active tuberculosis or active syphilis infection. History of immunodeficiency or positive for human immunodeficiency virus (HIV) antibodies test. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Participants with inactive HBV infection must receive antiviral therapy throughout the study. History of other primary malignancies within 5 years prior to randomization. Known hypersensitivity to any component of the investigational product. Females who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study period. Any condition that, in the opinion of the investigator, would make the participant unsuitable for study participation.
引自 ClinicalTrials.gov, NCT07739758, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07739758,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。